Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Mannkind Corp (MNKD)

Mannkind Corp (MNKD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,185,885
  • Shares Outstanding, K 249,660
  • Annual Sales, $ 65,140 K
  • Annual Income, $ -57,240 K
  • 60-Month Beta 1.97
  • Price/Sales 17.86
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade MNKD with:

Options Overview Details

View History
  • Implied Volatility 91.17%
  • Historical Volatility 34.20%
  • IV Percentile 33%
  • IV Rank 8.20%
  • IV High 409.00% on 09/28/20
  • IV Low 62.76% on 08/11/21
  • Put/Call Vol Ratio 0.02
  • Today's Volume 1,885
  • Volume Avg (30-Day) 1,694
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 44,149
  • Open Int (30-Day) 36,061

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.05
  • Number of Estimates 3
  • High Estimate -0.04
  • Low Estimate -0.06
  • Prior Year -0.05
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.32 +8.33%
on 09/20/21
5.02 -6.77%
on 09/14/21
+0.24 (+5.41%)
since 08/24/21
3-Month
3.78 +23.81%
on 08/12/21
5.53 -15.37%
on 06/30/21
-0.03 (-0.64%)
since 06/24/21
52-Week
1.78 +162.92%
on 10/06/20
6.25 -25.12%
on 02/24/21
+2.85 (+155.74%)
since 09/24/20

Most Recent Stories

More News
Mannkind Corporation Participating at Upcoming Conferences

MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that...

MNKD : 4.68 (-1.47%)
MannKind Corporation to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that...

MNKD : 4.68 (-1.47%)
United Therapeutics Presents Tyvaso DPI™ BREEZE Clinical Data At The European Respiratory Society International Congress 2021

and , Sept. 7, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today presented new clinical data from the study evaluating Tyvaso DPI™ (treprostinil) in patients with pulmonary...

UTHR : 195.10 (-2.68%)
MNKD : 4.68 (-1.47%)
United Therapeutics to Present Tyvaso DPI™ BREEZE Clinical Data at the European Respiratory Society International Congress 2021

and , /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced it will present data from a clinical trial studying Tyvaso DPI™ (treprostinil) in patients with pulmonary arterial...

UTHR : 195.10 (-2.68%)
MNKD : 4.68 (-1.47%)
MannKind (MNKD) Reports Q2 Loss, Tops Revenue Estimates

MannKind (MNKD) delivered earnings and revenue surprises of -25.00% and 31.12%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

MNKD : 4.68 (-1.47%)
United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Stock Up

United Therapeutics (UTHR) second-quarter earnings and sales beat estimates. Higher sales of Orenitram, Unituxin and Tyvaso mainly drive the top line in the quarter.

MNKD : 4.68 (-1.47%)
LLY : 231.68 (-0.22%)
MDT : 130.02 (-0.47%)
UTHR : 195.10 (-2.68%)
MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI™ (aviptadil) Based On The Technosphere® Platform

/PRNewswire/ -- (Nasdaq: MNKD) has partnered with NRx Pharmaceuticals (Nasdaq: NRXP) (NRx) to evaluate the feasibility of formulating a dry powder formulation of ZYESAMI (aviptadil), a synthetic form...

NRXP : 9.42 (-5.89%)
MNKD : 4.68 (-1.47%)
NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMI™ (aviptadil) Inhaler for Respiratory Conditions

/PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has signed an agreement with MannKind Corporation to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form...

NRXP : 9.42 (-5.89%)
MNKD : 4.68 (-1.47%)
MannKind Corporation to Hold 2021 Second Quarter Financial Results Conference Call on August 11, 2021

MannKind Corporation (Nasdaq:MNKD) will release its 2021 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM...

MNKD : 4.68 (-1.47%)
MannKind Corporation to Participate in the BTIG Virtual Biotechnology Conference 2021

MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that...

MNKD : 4.68 (-1.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder...

See More

Key Turning Points

3rd Resistance Point 5.02
2nd Resistance Point 4.93
1st Resistance Point 4.81
Last Price 4.68
1st Support Level 4.60
2nd Support Level 4.51
3rd Support Level 4.39

See More

52-Week High 6.25
Last Price 4.68
Fibonacci 61.8% 4.54
Fibonacci 50% 4.01
Fibonacci 38.2% 3.49
52-Week Low 1.78

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar